Business Areas
Improving the quality of our lives through state-of-the-art R&D capabilities.
Life science, with outstanding R&D competence and new drugs that have been approved by USFDA for the first time in Korea, is LG Chem's new growth engine in the mid to long term.
We are aggressively making inroads in overseas markets and expanding pipelines for new drugs through constant investment and reinforcing R&D, with aspirations to become one of the top global pharmaceutical companies.
Sales
0.63KRW trillion
2019
0.66KRW trillion
2020
0.8KRW trillion
2021
  • 1961 Obtained the drug manufacturing permit
  • 1984 Established Pharmaceuticals
    business division
  • 1991 Developed World’s first
    4th generation Cephalosporin
  • 1996 Won the first prequalification by the WHO with Hepatitis B vaccine Euvax B
  • 2003 1st Korean NCE approved by
    USA FDA(Factive)
  • 2012 Released the first Korean diabetes drug Zemiglo
  • 2017 Merged with
    LG Life Sciences
  • 2019 Established the Global Innovation Center in Boston, US
  • 2021 Established a joint venture sales corporation LG Jiansheng Life Sciences in ChinaSucceeded in phase II clinical trial of the new gout drug in the US
Division
Primary Care (PC) Primary Care (PC)
Special Care (SC) Special Care (SC)
Aesthetic Aesthetic
R&D Pipeline
R&D Pipeline
Core Products
Eutropin Eutropin
Hyruan One Hyruan One
Zemiglo Zemimet SR Tab Zemiglo Zemimet SR Tab
Eucept Eucept
YVOIRE YVOIRE
Press Releases
LG Chem’s New Drug for Obesity Receives Additional Orphan Drug Designation by the US FDA 2022.06.16
LG Chem’s 4th anti-cancer milestone enters Phase I clinical trial in the US 2022.05.12
LG Chem’s new drug substances on atopic dermatitis proceeds to Phase II trials following ulcerative colitis trials in China 2022.04.20
more
Video
Select Opening of a Global Innovation Center Opening of a Global Innovation Center